文献速递流行病学与生物统计医学教育与科研方法

印度临床试验方案中残疾人群参与障碍的回顾性分析

Understanding participation of persons with disabilities in clinical trial research in India-a retrospective analysis of inclusive language of protocols.
PubMed 文献 · Trials · 2026-03-24

该研究回顾分析2017年1月至2024年12月印度相关临床试验方案,评估基于残疾的排除性语言使用情况。共纳入271个方案,117个(43.2%)存在126处残疾相关排除表述,其中神经残疾占69.8%,仅11.9%明确依据诊断标准。研究提示需推广支持性、透明且非排除性的方案语言。

要点

  • 43.2%的印度相关临床试验方案存在残疾相关排除性语言。
  • 神经残疾排除占69.8%,仅11.9%有明确诊断依据。
  • 5.9%方案要求增强认知能力知情同意,但无支持决策机制。

核心结论

  • 超过三分之一的临床试验方案存在模糊资格标准及排除性语言,可能潜在排除残疾人群。

研究设计与样本

  • 回顾性混合方法分析,检索2017年1月至2024年12月印度相关已发表临床试验方案,源自国家和国际数据库。
  • 共筛选11975条记录,最终纳入271个临床试验方案。
  • 采用结构化五步编码流程,按RPWD法案七个残疾域评估排除模式。

主要发现

  • 117个(43.2%)方案报告126处残疾相关排除性语言。
  • 神经残疾排除占69.8%,言语和语言障碍占16.6%,血液疾病占9.5%,运动残疾占3.1%,听力和视力相关残疾占1%。
  • 仅11.9%的排除明确基于诊断标准,17.4%未说明任何理由。
  • 3期试验排除性语言占49.2%,国际或多中心试验占54.7%,印度国内试验占44.4%。
  • 5.9%方案要求增强认知能力以知情同意,但均未包含支持决策机制。

临床怎么用

  • 提示研究者在撰写方案时避免模糊或排除性语言,明确排除依据并提供支持机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The under-representation of vulnerable groups in clinical trials, including persons with disabilities, could affect the applicability of trial findings to real-world public health interventions. We undertook this study to assess the extent to which persons with disabilities are excluded due to non-inclusionary language use in protocols from clinical trial research in India. METHODS: We conducted a retrospective mixed-methods analysis of fully published clinical trial protocols relevant to India (January 2017 to December 2024), sourced from national and international databases. Inclusion and exclusion criteria were analyzed with a focus on seven disability domains as defined by the Rights of Persons with Disabilities (RPWD) Act: locomotor disabilities, blood disorders, neurological disabilities, speech and language-related disabilities, hearing and vision-related disabilities, intellectual disabilities, and others. We executed a structured five-step coding process to assess patterns of disability-based exclusion in clinical trial protocols, determining whether exclusions were based on specific diagnoses or broad descriptions and whether justifications or supportive mechanisms were provided. To contextualize the findings, additional information regarding the trial phase, study location, and disease focus was extracted. An inductive analysis explored the language and rationale being employed for disability-related exclusions. RESULTS: Of the 11,975 records screened, 271 clinical trial protocols met the inclusion criteria. Among these, 117 (43.2%) protocols reported 126 instances of disability-related exclusionary language in the eligibility criteria. Exclusionary language pertaining to neurological disabilities accounted for the majority of exclusions (69.8%), followed by speech and language impairments (16.6%), blood disorders (9.5%), locomotor disabilities (3.1%), and hearing and vision-related disabilities (1%). Only 11.9% of these exclusions were explicitly justified based on diagnostic criteria, whereas 17.4% lacked any stated justification for disability-based exclusions. Exclusionary languages were notably higher in phase 3 trials (49.2%) and in international or multicentric trials (54.7%) compared to trials conducted in India (44.4%). Additionally, 5.9% of protocols specified a requirement for enhanced cognitive ability for informed consent, yet none included provisions for supportive decision-making mechanisms. INTERPRETATION AND CONCLUSIONS: Over one-third of clinical trial protocols had ambiguous eligibility criteria and exclusionary language which may potentially exclude persons with disabilities. This highlights the need for promoting the use of supportive, transparent, and non-exclusionary trial protocol language.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Nagarajan K, Muniyandi M, Jeyachithra AV, et al. Understanding participation of persons with disabilities in clinical trial research in India-a retrospective analysis of inclusive language of protocols. Trials. 2026. PMID: 41877209. doi:10.1186/s13063-026-09590-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。